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Since its discovery, the study of the biological role of α-synuclein and its pathological
implications has been the subject of increasing interest. The propensity to adopt
different conformational states governing its aggregation and fibrillation makes this
small 14-kDa cytosolic protein one of the main etiologic factors associated with
degenerative disorders known as synucleinopathies. The structure, function, and toxicity
of α-synuclein and the possibility of different therapeutic approaches to target the
protein have been extensively investigated and reviewed. One intriguing characteristic of
α-synuclein is the different ways in which it interacts with lipids. Though in-depth studies
have been carried out in this field, the information they have produced is puzzling and
the precise role of lipids in α-synuclein biology and pathology and vice versa is still largely
unknown. Here we provide an overview and discussion of the main findings relating to
α-synuclein/lipid interaction and its involvement in the modulation of lipid metabolism
and signaling.
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INTRODUCTION
α-Synuclein is a cytosolic protein of 140 amino acids which was discovered in 1988 together with
β- and γ-synucleins by Maroteaux et al. (1988). The name α-synuclein derives from the fact that it
was originally described as being located in presynaptic endings and also as being associated with
nuclear envelopes. In the central nervous system, α-synuclein is abundantly expressed in neurons
of different brain areas such as the neocortex, hippocampus, SN, thalamus, and cerebellum (Iwai
et al., 1995; Asi et al., 2014). α-Synuclein is also present in the peripheral nervous system, muscle,
liver, heart, lungs, kidney, hematopoietic cells of the bone marrow, and circulating blood cells
Abbreviations: AA, arachidonic acid; Chol, cholesterol; DHA, docosahexaenoic acid; FFA, free fatty acids; HMG-CoA,
3-hydroxy-3-methylglutaryl coenzyme A; LB, Lewy bodies; LD, lipid droplet; PA, phosphatidic acid; PC, phosphatidylcholine;
PD, Parkinson’s disease; PE, phosphatidylethanolamine; PI, phosphatidylinositol; PL, phospholipid; PLA2, phospholipases
A2; PLC, phospholipase C; PLD, phospholipase D; PS, phosphatidylserine; PUFA, polyunsaturated fatty acids; SN, substantia
nigra pars compacta; TAGs, triacylglycerols.
Frontiers in Cellular Neuroscience | www.frontiersin.org 1 May 2019 | Volume 13 | Article 175
fncel-13-00175 April 29, 2019 Time: 15:11 # 2
Alza et al. α Synuclein and Lipids: Biological Intersections
(Gardai et al., 2013; Burré et al., 2018; Mohamed Badawy et al.,
2018). β-Synuclein is also located at presynaptic terminals in
the central nervous system (Jakes et al., 1994; Wilhelm et al.,
2014) while γ-synuclein is primarily expressed in the peripheral
nervous system, and the ocular and adipose tissues (Buchman
et al., 1998; Surguchov et al., 2001). It has been reported
that γ-synuclein is overexpressed in different human tumors
(Bruening et al., 2000; Guo et al., 2007; Hibi et al., 2009).
Though numerous studies have been carried out on the
biology of α-synuclein, its physiological function remains a
matter of debate. The search for a fuller understanding of
this function is driven by the fact that it has been linked
with several devastating diseases known as synucleinopathies,
including neurodegenerative disorders such as: PD, Lewy body
dementia, neurodegeneration with brain iron accumulation,
Krabbe disease, dementia with LB, diffuse Lewy body disease,
Lewy body variant of Alzheimer’s disease, among others (Burré,
2015; Burré et al., 2018).
Parkinson’s disease is the second most prevalent
neurodegenerative age-associated disorder after Alzheimer’s
disease and is mainly characterized by movement impairments
such as resting tremor, bradykinesia, and rigidity. The loss of
dopaminergic neurons in the SN has been identified as the
cause of the typical motor disablement (Dunnett and Björklund,
1999). Current therapies focus on the reestablishment of the
neurotransmitter dopamine for controlling motor symptoms,
but specific treatments are still not available owing mainly to
a lack of knowledge of the molecular mechanisms that trigger
neuronal degeneration and death (Oertel and Schulz, 2016).
Since diagnosis occurs when the loss of dopaminergic neurons is
massive, a better understanding of the molecular events involved
in the neurodegenerative process would undoubtedly help in the
discovery of specific treatments.
Parkinson’s disease is a multifactorial neurodegenerative
disorder whose etiopathogenesis is still largely unknown,
though a common finding in patients’ brain is the abnormal
accumulation, and aggregation of α-synuclein. Intracellular
aggregates of α-synuclein, named LB, constitute the histological
hallmark of the PD brain. LB are also the main histopathological
findings in the above-mentioned synucleinopathies. The role
of α-synuclein as one of the leading causes of dopaminergic
cell death was described after the identification of the first
missense mutations (A30P, E46K, and A53T) in the SNCA
gene (Polymeropoulos et al., 1997; Krüger et al., 1998; Zarranz
et al., 2004). The involvement of α-synuclein mutants in familial
inherited PD has been confirmed by genome-wide association
studies (Chang et al., 2017). In addition, SNCA duplication and
triplication causing elevated levels of the protein are associated
with early-onset PD (Singleton et al., 2003; Chartier-Harlin et al.,
2004). Although the α-synuclein protein does not display any
mutations in sporadic PD and LB dementia, its involvement
in neuronal damage is widely recognized. Of the several
mechanisms that could be responsible for the association of
α-synuclein with PD pathogenesis, there is an overall consensus
that its aggregation leading to the formation of oligomers is a
central event related to neuronal dysfunction (Ingelsson, 2016;
Bengoa-Vergniory et al., 2017). These α-synuclein oligomeric
forms are considered the most toxic species, disrupting
cellular homeostasis and triggering neuronal death. Moreover,
α-synuclein can exert a deleterious effect by spreading from cell
to cell and thus contributing to progressive neurodegeneration
(Desplats et al., 2009). Identification of the factors promoting the
toxic conversion of mutated or wild-type forms of α-synuclein is
a topic of intense interest. Deeper insight into the physiological
function and pathological features of α-synuclein would not only
contribute toward a better understanding of the pathogenesis but
also help to develop biomarkers for early disease detection and
progression and to design specific disease-modifying therapies
for synucleinopathies.
The α-synuclein protein is composed of three well-described
regions that confer the biological and functional characteristics
that implicate it in PD pathology. The N-terminal domain
comprises residues 1–60 and bestows lipid binding properties on
the protein, in particular, the ability to interact with membranes
and lipid micelles. This distinctive feature of α-synuclein is
explained by the presence of amphipathic repeats of 11 amino
acids, predominantly with the highly conserved KTKEGV motif,
similar to that present in apolipoprotein domains (Bussell and
Eliezer, 2003). This structural characteristic is shared with
β- and γ-synucleins (Clayton and George, 1998). The missense
mutations A53T, A30P, H50Q, G51D, A53E, and E46K reside
in the N-terminal domain of α-synuclein (Polymeropoulos
et al., 1997; Krüger et al., 1998; Zarranz et al., 2004; Flagmeier
et al., 2016). The central hydrophobic region (residues 61–95)
called NAC (non-amyloid β component) is essential for the
conformational change of α-synuclein from random coil to
β-sheets, leading to aggregation, and fibrillation (El-Agnaf et al.,
1998; Rodriguez et al., 2015). Giasson et al. (2001) demonstrated
through different assays that amino acids 71–82 represent the
specific sequence of the NAC core which is necessarily involved
in α-synuclein fibrillation. Biophysical studies using methods like
nuclear magnetic resonance, electron paramagnetic resonance,
circular dichroism and transmission electron microscopy,with
recombinant proteins of α-synuclein and synthetic fragments
of NAC were the first and are still used to demonstrate
the importance of this region in the fibrillation pathway (El-
Agnaf et al., 1998; Giasson et al., 2001; Der-Sarkissiant et al.,
2003; Tashiro et al., 2008; Waxman et al., 2009; Shaltiel-
Karyo et al., 2010). The elimination of the NAC region or its
targeting with antibodies showed to inhibit aggregation and
toxicity in cell culture (Lynch et al., 2008; Luk et al., 2009).
In vivo models were also used to evaluate the pathological
effects of this region. For instance, the deletion of amino
acids 71–82 in Drosophila prevents α-synuclein aggregation and
neurotoxicity, thus testifying to the importance of this region
in the pathogenicity of the protein (Periquet et al., 2007).
Differences in the amino acid sequence of the NAC region
have been attributed to be responsible for the non-fibrillation
feature of β-synuclein (Uversky and Fink, 2002). The third
region of α-synuclein, enriched in glutamate, aspartate, and
proline residues, is the acidic C-terminal domain (residues
96–140). It constitutes the main site of post-translational
modifications, such as phosphorylation and nitration, although
other modifications (ubiquitination, glycation, and methionine
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oxidation) also occur in the N-terminal domain (Chen et al.,
2019). These modifications alter α-synuclein structure and
provoke changes in hydrophobicity and protein-protein and
protein-lipid interactions (Burré et al., 2018). Oxidation,
nitration and phosphorylation are thought to contribute to
different extents to α-synuclein aggregation and fibrillation
(Barrett and Timothy Greenamyre, 2015). Phosphorylation is
the most relevant post-translational modification related to
synucleinopathies. Increased levels of the phosphorylated protein
at serine 87 have been found in human brains from LB
dementia patients (Paleologou et al., 2010) and at serine 129
in LB from PD patients (Fujiwara et al., 2002). Although this
latter has been widely investigated, its role on the pathogenesis
of PD has not been determined yet. Some authors propose
that it is implicated in α-synuclein pathological aggregation
(Fujiwara et al., 2002) whereas others suggest that it has a
protective role on the aggregation and toxicity (Oueslati et al.,
2010; Chen et al., 2019). The protein also suffers C-terminal
truncation linked to an increase of α-synuclein aggregation
in vitro (Murray et al., 2003); the loss of SN neurons in
transgenic mice overexpressing this form has been reported
(Wakamatsu et al., 2008). Both the N- and C-terminal domains
have also been involved in the interaction with proteins and
metal ions (Miotto et al., 2014; Carboni and Lingor, 2015;
Billings et al., 2016).
From a conformational point of view, under physiological
conditions α-synuclein is considered to be an intrinsically
unstructured protein. The soluble α-synuclein in the cytosol
is natively unfolded (Burré et al., 2013). Conformational
flexibility is largely attributed to the α-synuclein structure
because it can adopt a range of conformations depending
on its interactions with membranes or proteins (Lashuel
et al., 2013). When α-synuclein/PL interaction occurs, the
N-terminal domain takes on an α-helical configuration that
occurs physiologically in a dynamic equilibrium with the soluble
state (Eliezer et al., 2001). An α-helical homo-tetramer of the
protein has recently been identified in neurons and other cells
(Bartels et al., 2011; Wang et al., 2011; Fanning et al., 2018),
occurring in equilibrium with α-synuclein monomers. As the
tetramer is resistant to pathological aggregation, the promotion
of its formation could be protective against α-synuclein
oligomerization (Bartels et al., 2011; Dettmer et al., 2013,
2015a,b, 2017). Moreover, under pathological conditions, the
induction of α-synuclein aggregation results in the formation of
an initial population of oligomers enriched in insoluble cross-
β-sheets (Conway et al., 2000; Pineda and Burré, 2017). These
species may act as nuclei for the next steps of elongation
and assembly into fibrils, which are finally deposited in LB
(Wood et al., 1999; Lashuel et al., 2013). Another proposed
mechanism for the formation of fibrillar aggregates is the
lateral association of the oligomeric granules without nuclei
formation (Bhak et al., 2009; Makwana and Sundd, 2016).
Oxidative stress, post-translational modifications, accumulation
of α-synuclein and changes in the levels of metal ions, PL,
and fatty acids have been proposed as modulators of the
aggregation process (Ruipérez et al., 2010; Lashuel et al., 2013;
Galvagnion, 2017).
This review focuses on the intriguing characteristic of
α-synuclein to pleiotropically interact with and modulate a
variety of lipids and on how these interactions participate in the
protein’s biological and pathological functions.
FUNCTIONS OF α-SYNUCLEIN
The physiological cellular functions of α-synuclein are still a
matter of intense debate, despite continuous efforts over the
last 30 years to clarify the issue. Since it is highly concentrated
in presynaptic terminals, where it is associated with synaptic
vesicles (Maroteaux et al., 1988), the involvement of α-synuclein
in neurotransmission, and synaptic plasticity has been extensively
investigated (Burré, 2015; Zaltieri et al., 2015). Although
there is disagreement as to whether it promotes or inhibits
neurotransmitter release, it is well-established that α-synuclein
mediates this process by regulating the availability of synaptic
vesicles in different pools, facilitating their clustering, recycling,
and docking to the cell membrane (Chandra et al., 2005; Burré
et al., 2010; Zaltieri et al., 2015; Miraglia et al., 2018). The
involvement of α-synuclein in synaptic vesicle endocytosis has
been demonstrated (Vargas et al., 2014). In addition, α-synuclein
can act as a chaperone molecule thus contributing to the assembly
of the SNARE complex (Bonini and Giasson, 2005; Diao et al.,
2013; Burré et al., 2014). The modulation of dopamine levels
by α-synuclein has been demonstrated as a consequence of
the inhibition of the neurotransmitter synthesis through the
regulation of tyrosine hydroxylase activity (Abeliovich et al.,
2000; Peng, 2005) and the inhibition of the vesicular monoamine
transporter-2 (Guo et al., 2008). It also has a regulatory effect
on the targeting and activity of the dopamine transporter DAT
(Swant et al., 2011; Oaks et al., 2013; Butler et al., 2015).
α-Synuclein also has roles which are unrelated to synaptic
functions. Surguchev and Surguchov have reviewed recent
findings focused on its implication in the regulation of gene
expression (Surguchev and Surguchov, 2017). A plethora of
other biological functions have been attributed to α-synuclein
such as regulation of apoptosis, modulation of glucose and
calmodulin levels, and neuronal differentiation (Emamzadeh,
2016). Even though these latter functions have not been explored
in depth, they provide evidence for proposing α-synuclein as a
pleiotropic molecule.
β- and γ-synucleins have not been linked to the pathogenesis
of PD. However, several reports have shown that β-synuclein
has an inhibitory effect on the aggregation of α-synuclein
(Brown et al., 2016) suggesting a neuroprotective role against
synucleinopathies. Otherwise, it has been proposed that
γ-synuclein is involved in cancer progression and metastasis
(Hibi et al., 2009; Hua et al., 2009; Dunn et al., 2015).
α-SYNUCLEIN AND MEMBRANE LIPIDS
Although the native α-synuclein three-dimensional
conformation is still under discussion, differential folding states
for physiological and pathological conditions have been assigned.
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One of the cutting-edge questions is the role of membrane
lipids in α-synuclein conformation since protein-membrane
binding has been associated with both normal and pathological
functions. It has been reported that the α-synuclein/membrane
interaction induces different α-helix states that could participate
in protein function or drive aggregation (Bodner et al., 2010;
Dikiy and Eliezer, 2012; Fares et al., 2014; Ysselstein et al., 2015;
Burré et al., 2018; O’Leary et al., 2018). At the same time, the
targeting of α-synuclein in its different conformations at the
membrane surface can alter lipid composition, thus promoting
pathological effects (van Rooijen et al., 2009; Reynolds et al.,
2011; Tosatto et al., 2012; Hellstrand et al., 2013). A significant
body of experimental evidence reinforces the hypothesis that
oligomers, the initial state of protein aggregation, are the most
neurotoxic species because of their ability, after interaction, to
disrupt biological membranes (Danzer et al., 2007; Winner et al.,
2011; Fusco et al., 2017; Galvagnion, 2017).
The nature of the interactions between α-synuclein and PLs
has been extensively reviewed in several papers that mainly
address this topic through biophysical studies (Dikiy and Eliezer,
2012; Pineda and Burré, 2017; Burré et al., 2018; O’Leary and
Lee, 2018). Here we will discuss the most biologically relevant
findings. One of the points included in this section is how
specific PLs participate in the induction of conformational
changes of α-synuclein and how this affects its biological and/or
pathological functions.
After adipose tissue, the brain is the organ with the highest
lipid content. PL content in the brain is approximately 6% of
dry weight and is represented by two main classes of molecules:
glycerophospholipids and sphingolipids (Lahiri and Futerman,
2007). A glycerophospholipid molecule consists of two fatty
acids, one saturated and one unsaturated, esterified in sn-1
and sn-2 of the glycerol backbone, respectively. The brain is
particularly enriched in two PUFA: arachidonic acid (AA, 20:4-
ω-6) and docosahexaenoic acid (DHA, 22:6-ω-3) (Chen et al.,
2008). PLs are the main constituents of cellular membranes and
because of their amphipathic nature, they provide the necessary
biophysical environment for ensuring the proper functioning of
structural proteins, receptors, enzymes, and ion channels located
at the cell surface or in intracellular membranes.
The plasma and organelle membranes are asymmetric;
this characteristic determines specific and differential lipid
composition in the inner and the outer leaflets. PC, PE,
sphingomyelin, and Chol are the most abundant lipids in
the outer hemimembranes. PS and PI are acidic PLs and
are predominantly located in the inner hemimembranes. This
particular lipid composition is determinant for the formation
of lipid rafts, specific membrane liquid-ordered microdomains
that govern protein recruitment (van Meer et al., 2008;
Marquardt et al., 2015).
In native conditions, α-synuclein can be mainly found
in two states: a soluble unfolded monomeric form or a
membrane-associated multimeric form. The pathological state
of the protein is composed of predominantly β-sheet oligomers
and amyloid fibrils (Burré, 2015). PLs have been reported to
participate in and modulate the different states of α-synuclein.
Originally, α-synuclein was described as a monomer in
equilibrium between the cytosol and the membrane fraction
(i.e., plasma membrane or vesicles). The occurrence of these
two physiological states has generated some controversy, but
consensus has now been reached that α-synuclein mainly occurs
as an intrinsically disordered monomer (Burré et al., 2013). Very
recently, a helically folded tetramer of the soluble protein has
been described in equilibrium with the monomer (Bartels et al.,
2011; Wang et al., 2011; Fanning et al., 2018). Soluble α-synuclein
exists as a random coil three dimensional structure that increases
α-helical conformation after interacting with membrane PLs,
suggesting that protein/PL interaction triggers structural changes
that could modulate biological function (Davidson et al.,
1998; Zhu et al., 2003). Furthermore, biophysical studies using
tryptophan- and spin-labeled determinations demonstrated that
the portion of the protein that interacts with the membrane
adopts an α-helix conformation which is entirely buried within
the depth of the membrane whereas the rest of the segments
present lower membrane penetration and higher flexibility
(Bussell, 2005; Wietek et al., 2013).
The preferred PLs for α-synuclein membrane binding
are those with an acidic head group such as PS and PI
(Shvadchak et al., 2011). The charged nature of these PLs
makes lysine residues candidates for α-synuclein binding sites
(Jo et al., 2000; Perrin et al., 2000). The interaction between
the N-terminal of α-synuclein and PS seems to be critical
for C-terminal SNARE-dependent vesicle docking (Lou et al.,
2017). Since SNARE-dependent vesicle docking is necessary
for calcium-mediated neurotransmitter release, it is reasonable
to assume that α-synuclein/PS interaction is critical to the
neurotransmission process at the synapse. Indeed, as previously
mentioned, one of the best characterized biological functions
of α-synuclein is its participation in vesicle recycling (Scott
and Roy, 2012; Wang et al., 2014). Experiments performed in
giant unilamellar vesicles composed of different proportions of
dioleoyl-PC and several anionic PLs demonstrated that wild-
type α-synuclein binding is dependent on the presence of
negatively charged head groups. Binding to anionic PLs is
also dependent of the liquid-ordered state of the vesicles, thus
indicating that protein/membrane interactions are governed not
only by electrostatic forces but also by lipid packaging and
hydrophobic forces (O’Leary and Lee, 2018). The interaction of
β- and γ-synucleins with membranes depends on the presence of
PL acidic head group and is also determined by the curvature of
the binding surface (Ducas and Rhoades, 2012).
A fact that argues in favor of the role of α-synuclein/lipid
interaction in the etiopathogenesis of synucleinopathies is that
all missense mutations responsible for familial PD are localized
in the 11-residue repeat domain that has membrane-binding
properties; indeed, these mutations alter the lipid binding
properties (Jo et al., 2002; Fares et al., 2014; Ghosh et al.,
2014; Robotta et al., 2017). A30P and E46K mutants display
altered binding to anionic PLs, thus suggesting that membrane
interaction could be disrupted in the familial forms of PD
(Stöckl et al., 2008).
Binding to PS has been shown to induce an increase in
α-synuclein oligomerization, thus providing evidence of the role
of protein/PL interaction in the modulation of the pathological
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aggregation of the protein (Hu et al., 2016). After interacting
with PLs, the impairing effects of α-synuclein on biological
membranes could be explained by the increase in membrane
tension and lipid extraction that promote pore formation and
membrane lysis (Jo et al., 2000; Zhu et al., 2003; Tosatto et al.,
2012; Braun and Sachs, 2015; Pan et al., 2018). In line with this,
it has been proposed that the interaction between acidic PLs and
α-synuclein plays a role during nuclear extrusion in erythroblast
differentiation (Araki et al., 2018).
Phosphatidic acid (PA), another anionic PL, differs from PS,
and PI mainly in terms of the small size of its head group;
this particular characteristic allows its localization very close
to the hydrophobic core of the lipid bilayer. PA is also an
α-synuclein partner for membrane targeting (Perrin et al., 2000).
Specifically, PA esterified with saturated/monounsaturated fatty
acids is the preferred molecular species for α-synuclein binding
and also induces an enhancement in protein aggregation through
the induction of changes in the secondary structure (Mizuno
et al., 2017). It has been reported that α-synuclein overexpression
is also able to modulate enzyme pathways that produce PA
(Dikiy and Eliezer, 2012) (see the section “α-Synuclein and
Lipid Signaling”).
α-Synuclein has also been shown to be associated with
mitochondrial membranes (Ghio et al., 2016). Binding of
α-synuclein to mitochondrial membranes has been detected
in SN dopaminergic neurons from mice and human brain
(Li et al., 2007; Devi et al., 2008). The nature of protein
association with mitochondria was determined by using
liquid-disordered membranes enriched in cardiolipin, an
essential PL very abundant in the inner mitochondrial
membrane and also essential for organelle function.
Cardiolipin-mediated binding of α-synuclein could represent
a mechanism by which the cytosolic protein is targeted
to mitochondria (Ghio et al., 2016). Once attached to
the membrane surface, the protein is also able to extract
lipids, which could explain the loss of mitochondrial
integrity during dopaminergic neuronal degeneration
(Pozo Devoto and Falzone, 2017).
The structural changes that α-synuclein undergoes after
interacting with PLs in membranes and how these changes
contribute to amyloidogenesis is nevertheless still under
debate. There is agreement that acidic PLs are the preferred
lipids for membrane targeting and that the protein/lipid
ratio could be determinant for both biological function and
amyloidogenic propensity. Very recently, it has been shown
that the conformational state of α-synuclein depends on
the protein/lipid ratio. A high α-synuclein/lipid ratio would
promote protein/protein interaction and in consequence
increase the propensity to form oligomers enriched in β-sheet
conformation which in turn could also fibrillate and induce
amyloid aggregation (Powers et al., 2017; Terakawa et al.,
2018). A low α-synuclein/lipid ratio, on the other hand,
would establish a condition of protein dilution, thus blocking
amyloid fibrillation, and indeed maintaining physiological
interactions with the membrane (Terakawa et al., 2018).
Previously mentioned evidence describes the interaction of
α-synuclein with membranes in the absence of post-translational
modifications; however, it has been shown that post-translational
modifications such as phosphorylated or acetylated forms of
the protein would interact in a different way (Burré et al.,
2018). One of the physiologically relevant post-translational
modifications of α-synuclein is its acetylation in the N-terminal,
which enhances binding to PC, a zwitterionic PL presented
in micelles and small unilamellar vesicles with high curvature
(r∼16–20 nm). Chol, another important membrane constituent,
has been shown to reduce N-acetylated α-synuclein-PC binding.
These in vitro results reported by O’Leary and coworkers
suggest that N-acetylation promotes the binding of α-synuclein
to highly curved membranes and that Chol interferes with
this interaction (O’Leary et al., 2018). Moreover, N-acetylated
α-synuclein has been shown to diminish the aggregation
propensity triggered by ganglioside GM1 binding (Bartels
et al., 2014). Phosphorylated α-synuclein in serine 129 has
been studied in depth in the last decade, with disparate data
being reported in relation to membrane interaction. However,
the most accepted theory to emerge from in vitro and in vivo
experiments is that the phosphorylated form has an inhibitory
effect on α-synuclein association with the membrane (Fiske
et al., 2011; Kuwahara et al., 2012; Nübling et al., 2014;
Oueslati, 2016).
Phospholipids also participate in the spreading of α-synuclein,
mainly attributed to exosomes, and are thus involved in
synucleinopathy propagation. Mass spectrometry studies show
the presence of PC, PE, PI, PS, and the gangliosides GM2 and
GM3 in exosomes isolated from neuroblastoma cells (Marie et al.,
2015). Moreover, experiments carried out on small unilamellar
vesicles to ascertain the role of gangliosides in α-synuclein
conformation demonstrated that GM1 and GM3, as well as
exosomes, are able to accelerate the aggregation of the protein
(Marie et al., 2015).
Despite the mounting evidence mentioned above, the question
of how PL interaction intervenes in α-synuclein physiological and
pathological function remains unanswered (Figure 1). In order
to shed further light on the specific role of lipid interactions in
α-synuclein biology and pathology and how these interactions
occur in vivo, it is necessary to carry out additional experiments
using models that mimic living cell lipid composition, membrane
asymmetry, and the intracellular environment.
α-SYNUCLEIN AND LIPID DROPLETS
Neutral lipids are part of a large, heterogeneous family
of compounds with the distinctive characteristic of being
hydrophobic molecules. Another of their particular features is the
lack of charged groups. The two main classes of neutral lipids
in mammals are TAGs and Chol esters, both of which reside
in the cytosol, contained in a simple membrane-surrounded
organelle, the LD (Welte, 2015). LD membranes contain PLs,
unesterified Chol, and specific anchored proteins with signaling
and lipolytic functions (Gao et al., 2017; Sztalryd and Brasaemle,
2017); as highly dynamic storage organelles, they provide a
rapidly mobilizable TAG pool to act as an energy source or as a
fatty acid donor for lipid remodeling processes.
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FIGURE 1 | α-Synuclein/lipid interactions: from the plasma membrane to intracellular compartments and extracellular vesicles. Soluble α-synuclein exists as a
random coil three-dimensional structure. Membrane targeting with acidic PLs (PS and PI) triggers α-helical folding at the N-terminal domain. Protein pathological
conformation is predominantly represented by β-sheet oligomers and amyloid fibrils. α-Synuclein pathological aggregation is dependent on the protein/lipid ratio.
Spreading of α-synuclein, largely attributed to exosomes, is also regulated by its interaction with the PLs of the extracellular vesicles. Free fatty acids, mainly DHA,
are able to induce α-synuclein oligomerization. After the interaction with lipid peroxidation products, α-synuclein is prone to the formation of toxic stable oligomers.
α-Synuclein also regulates Chol efflux via ABCA1 transporter. DHA, docosahexaenoic acid; PA: phosphatidic acid; PI, phosphatidylinositol; PS, phosphatidylserine.
Though LDs are present in almost all cell types, their
major occurrence is in adipocytes and hepatocytes. They also
serve as cellular stress indicators and are associated with
pathological states including starvation, infection, cancer, and
liver steatosis (Gluchowski et al., 2017; Tirinato et al., 2017).
Scarce information on the precise function of LDs on the nervous
system is available in the literature. However, recent works
correlate the appearance of LDs with pathological situations
in neurodegenerative disorders. Glial cells were reported to be
LD-positive cells that accumulate neutral lipids in response to
the injury of neighbor neurons in several neurodegenerative
conditions (Liu et al., 2015; Cabirol-Pol et al., 2018). LDs
were detected in Aplysia axons and neuronal primary cultures
and neurons of Huntington’s disease models (Savage et al.,
1987; Martinez-Vicente et al., 2010; Welte, 2015). In addition,
iron accumulation, an event intensively described in several
neurodegenerative processes and also in PD, has been shown to
increase LD formation in dopaminergic neurons (Salvador, 2010;
Schneider and Bhatia, 2012; Sánchez Campos et al., 2015).
A large body of evidence points to α-synuclein/LD interaction.
Experiments performed in vitro demonstrate that α-synuclein
binds to artificial 60 nm diameter LDs (Thiam et al.,
2013). Moreover, it has been shown that in HeLa cells
incubated with a high concentration of fatty acid, wild-type
α-synuclein translocates from the cytosol to the surface of
LDs (Colebc et al., 2002). α-Synuclein mutants display a different
behavior: whereas A53T strongly associates with LDs, A30P
remains cytosolic. These findings were corroborated by the
heterologous expression of human α-synuclein in Saccharomyces
cerevisiae (Sere et al., 2010). The biological significance of
the α-synuclein-induced increase in LDs observed in yeasts
was addressed in a mutant strain unable to synthesize neutral
lipids and more tolerant to α-synuclein overexpression (Sere
et al., 2010). In line with these findings, we recently reported
that A53T α-synuclein overexpression in dopaminergic neurons
induces an increase in TAG production and LD accumulation
(Sánchez Campos et al., 2018). Fe exposure in A53T α-synuclein-
overexpressing neurons increases protein aggregation, thus also
augmenting TAG and LD content (Sánchez Campos et al., 2018).
The nature of the α-synuclein/LD interaction has been shown
to depend on PL packing at the LD membrane, being not fully
packed monolayers the preferred surface for protein binding
(Thiam et al., 2013). LD surface has been described as a higher
hydrophobic environment than the PL bilayer (Thiam et al., 2013;
Kory et al., 2016). The need for this highly hydrophobic organelle
has been reported in other biological processes such as protein
viral assembly (Ogawa et al., 2009; Welte and Gould, 2017).
The relevance of the biological interaction between
α-synuclein/LD has not been explored in vivo, but it can be
proposed that LDs are early markers of neurodegenerative
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processes and the characteristic of these vesicles make them good
candidates for the modulation of α-synuclein conformational
changes and pathological aggregation. Further research is
required for a deeper understanding of these phenomena and
their implications in synucleinopathies (Figure 1).
α-SYNUCLEIN AND FATTY ACIDS
Another interesting discussion is the role of FFA in α-synuclein
biology. Brain membranes exclusively contain a high
concentration of PUFA, DHA, and AA being the most abundant.
DHA is an essential fatty acid that needs to be incorporated
from the diet, and disturbances in its metabolism have been
reported to be associated with both neurodevelopment and
neurodegenerative disorders (Chen et al., 2008). Some years
ago, several in vitro observations proposed that α-synuclein
could act as a fatty acid binding protein in the brain (Sharon
et al., 2001). Soon afterward, PUFA were shown to promote the
assembly of α-synuclein soluble oligomers (Sharon et al., 2003a;
Karube et al., 2008). Both DHA and to a lesser extent AA are
able to induce α-synuclein oligomerization as demonstrated
by transmission electron microscopy, electrophoresis of native
gels, and fluorescence assays with thioflavin T (Broersen et al.,
2006). Relative concentrations of α-synuclein and DHA appear
to govern the free and bound states of the protein and also
its conformational changes, by increasing its α-helix structure
(Sharon et al., 2001; Fecchio et al., 2018). Moreover, prolonged
exposure to PUFA triggers the formation of α-synuclein fibrils.
The establishment of oligomeric or fibrillar conformations in the
presence of DHA depends on the protein/FFA ratio. Whereas
fibril formation is favored by a 1:10 molar ratio, oligomeric
species characterized by lack of seeding properties for fibrillation
are stabilized by a 1:50 ratio (De Franceschi et al., 2011). The
general consensus among the broad range of studies on the
effect of fatty acids on α-synuclein biology is that PUFA elicit the
formation of diverse oligomeric forms with differential structural
and biological properties (Perrin et al., 2001; Fecchio et al.,
2013). Oligomeric species generated in vitro by DHA exposure
showed a partial α-helical structure, with the capacity to alter the
membrane permeability and thus to trigger cytotoxicity (Fecchio
et al., 2013). β- and γ-synucleins are also able to interact with
PUFA trough their lipid binding domain (Perrin et al., 2001).
A rise in free DHA levels in cytosolic fractions has already
been found in brains of patients with PD and LB dementia,
and this could be responsible for the oligomerization of
α-synuclein and the underlying neuronal damage (Sharon
et al., 2003b). Biophysical studies combined with transmission
electron microscopy demonstrated that DHA in solution
is able to form oil droplets. These oil droplets can be
remodeled by α-synuclein, reducing their size and fatty acid
concentration (Broersen et al., 2006; De Franceschi et al., 2009;
Figure 1). In addition, the interaction with DHA droplets
promotes differential susceptibility of proteolytic degradation
(De Franceschi et al., 2009).
α-Synuclein has been shown not only to form covalent bonds
with DHA but also to act as a scavenger of the oxidation
products of DHA, mainly through its histidine residue in
position 50 (De Franceschi et al., 2017). Moreover, it has been
observed that lysine residues, acting as nucleophiles, are able
to interact with electrophilic products of lipid peroxidation and
that this protective effect is weakened after lysine acetylation.
Additionally, α-synuclein binding to liposomes containing PC
and PA enriched with PUFA has been reported to have a
protective effect against nitration and oxidation (Trostchansky
et al., 2006). The interaction of α-synuclein with 4-hydroxy-
2-nonenal, one of the main products of PUFA peroxidation,
is able to promote the formation of toxic stable oligomers,
and also prevent the passage toward the final state of fibrils
(Qin et al., 2007; Puspita et al., 2017; Shamoto-Nagai et al.,
2018). Furthermore, dopaminergic cells incubated with free
PUFA showed decreased viability associated with the presence of
oligomeric α-synuclein (Assayag et al., 2007).
The reported findings highlight the connection between
oligomeric α-synuclein and fatty acid oxidation in dopaminergic
toxicity, suggesting the existence of a positive loop of increased
damage when α-synuclein is allowed to interact with PUFA and
their oxidation products. One of the most accepted theories for
the onset of neurodegenerative diseases associated with aging
postulates the increase in oxidative stress as one of the main
gating factors. Since the well-described decrease in antioxidant
defenses associated with the aging process increases oxidative
stress, it is arguable that lipid peroxides could be available for
the interaction with α-synuclein thus triggering the generation
of toxic oligomeric forms. Moreover, the extensively documented
decrease in brain PUFA content during aging could also be
responsible for an increase in saturated PLs at the membranes
that in turn could decrease the association with α-synuclein and
augment the cytosolic levels of the protein available for binding
with lipid peroxides (López et al., 1995; Giusto et al., 2002; Mateos
et al., 2010; Ledesma et al., 2012). Studies on oligodendroglial cells
overexpressing the A53T mutant have shown that oxidative stress
exposure after supplementation with DHA is able to promote
the genesis of inclusion bodies whose composition includes
phosphorylated α-synuclein (serine 129) and ubiquitinated and
SUMOylated proteins, all reported to be aggregation inducers
(Riedel et al., 2011).
A number of PD animal models have been used to
corroborate some of the above-discussed in vitro results. The
use of transgenic mice overexpressing different α-synuclein
forms and subjected to high-DHA diet has served to support
some of the earlier findings. Yakunin et al. (2012) showed
increased accumulation of soluble and insoluble α-synuclein
forms accompanied by astrocytosis and neuritic defects in
an A53T transgenic mouse model fed a DHA-enriched diet.
Experiments in vivo with transgenic mice expressing the A53T
α-synuclein mutant demonstrated that a diet with high DHA
content reduces lipoxidative damage (Muntané et al., 2010).
A very recent report demonstrated that a diet supplemented with
n-3 PUFA promotes the accumulation of a 42-kDa oligomeric
form of the protein (Yakunin et al., 2012; Coulombe et al.,
2018). Analysis of post-mortem human brains corroborates some
of the previous in vitro and in vivo experimental findings.
Protein profile of synucleinopathy patients was enriched with
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both soluble and insoluble oligomers and a positive correlation
between the accumulation of α-synuclein oligomers and cytosolic
DHA content was reported (Sharon et al., 2003a,b).
All these findings postulate DHA in soluble and esterified
forms as an important candidate for modulating both the
targeting and the biological function of α-synuclein. Thus, the
regulation of DHA availability under pathological conditions
could be an important event for regulating α-synuclein
oligomerization and aggregation processes. In this sense, lipid
pathways involved in DHA acylation, and deacylation could
constitute a promising strategy for new therapeutic approaches
in synucleinopathies (see section “α-Synuclein and Lipid
Signaling”) (Figures 1, 3).
α-SYNUCLEIN AND LIPID METABOLISM
The clear involvement of a crosstalk between α-synuclein and
lipid metabolism was investigated by Murphy’s group using
protein knock-out mice (Castagnet et al., 2005; Golovko et al.,
2006, 2007, 2009; Barceló-Coblijn et al., 2007; Golovko and
Murphy, 2008). SNCA (−/−) mice oppositely metabolize the
two main brain PUFA, AA, and DHA. The lower intake of AA
reported both in neurons and astrocytes from SNCA (−/−)
mice was reverted by exogenous wild-type α-synuclein through
the modulation of acyl-CoA synthetase activity (Golovko et al.,
2006). However, DHA turnover and acylation in PE, PI, and
PS was found to be increased in SNCA (−/−) mice when
compared with SNCA (+/+) mice (Golovko et al., 2007).
This differential effect in AA and DHA metabolism as a
consequence of the silencing of α-synuclein argues in favor of
compensatory mechanisms associated with PUFA content in
brain membranes (Figure 2).
Several experimental evidences have demonstrated that both
the absence and the overexpression of α-synuclein are able to
disturb lipid homeostasis by increasing neutral lipid storage. In
astrocytes and whole brain, the absence of α-synuclein switches
the distribution of fatty acids to neutral lipid reserves and also
increases neutral lipid mass (Castagnet et al., 2005; Barceló-
Coblijn et al., 2007). Surprisingly, α-synuclein overexpression
gives rise to abnormal lipid metabolism in yeasts, characterized
by an increase in LD content (Outeiro and Lindquist, 2003; Su
et al., 2010). In line with this, overexpression of wild-type and
mutant forms of α-synuclein triggers the accumulation of LDs in
HeLa cells, and in human-induced pluripotent stem cell (Colebc
et al., 2002; Fanning et al., 2018). Regarding these findings, it
can be suggested that physiological levels of α-synuclein are
necessary for lipid homeostasis. γ-Synuclein, another member of
the synuclein family, has also been implicated in the maintenance
of LD formation and in the modulation of lipid composition in
adipocytes and the nervous system in mice (Guschina et al., 2011;
Voshol et al., 2012).
In harmony with these results, a recent study in our laboratory
showed that the overexpression of A53T α-synuclein induces an
increase in TAG content and the accumulation of LDs in N27
dopaminergic neurons (Sánchez Campos et al., 2018). The rise
in neuronal TAG content was associated with increased fatty acid
synthase expression and Acyl-CoA synthetase activity, with no
variations in TAG lipase activity or in fatty acid β-oxidation,
thus demonstrating that the overexpression of A53T α-synuclein
triggers a lipid metabolic switch in dopaminergic neurons.
Pharmacological blockage of TAG de novo synthesis renders
the neurons more susceptible to iron-induced oxidative stress
(Sánchez Campos et al., 2018).
α-Synuclein biology and Chol metabolism have been shown
to interact in many different ways. Such intersections regulate
FIGURE 2 | Crosstalk between α-synuclein and lipid metabolism. Knock-down and overexpression of α-synuclein have demonstrated the involvement of the protein
in lipid metabolism. In α-synuclein knock-out mice, AA and DHA, the main polyunsaturated fatty acids in the brain, are oppositely metabolized: whereas AA intake is
diminished, DHA turnover and acylation in PI and PS are increased. α-Synuclein overexpression triggers an increase in TAG content and LD accumulation by
stimulation of acyl-CoA synthetase activity and probably the modulation of HMG-CoA reductase. AA, arachidonic acid; DHA, docosahexaenoic acid; HMG-CoA,
3-Hydroxy-3-methyl glutaryl coenzyme A; LD, lipid droplet; PI, phosphatidylinositol; PS, phosphatidylserine; TAG, triacylglycerol.
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one another in a complex and not yet fully understood manner
(Yeger-Lotem et al., 2009; Galvagnion, 2017). Controversial
information coexists regarding plasma Chol level since it has
been considered as either positive or negative risk factor for
PD, or even not being linked at all to PD (Galvagnion, 2017).
More concrete evidence links oxidized Chol derivatives with
the onset and progression of PD (Bosco et al., 2006; Marwarha
and Ghribi, 2015). In this regard, 27-hydroxycholesterol, a
product of Chol oxidation, has been found to be increased
in the brain, cortex and plasma, of PD patients (Lee et al.,
2009; Seet et al., 2010; Cheng et al., 2011). Moreover,
exogenous 27-hydroxycholesterol is able to induce the expression
and accumulation of α-synuclein in human dopaminergic
neurons through a transcriptional mechanism mediated by the
transcription factor LXRβ (Marwarha et al., 2011). A possible
mechanism that supports these findings could be the regulation
of Chol eﬄux from neuronal cultures via ABCA1 transporter
associated with the increased levels of oxidative stress reported
in PD (Hsiao et al., 2017).
Regarding Chol biosynthesis, in silico analysis from the
Yeger-Lotem laboratory identified the ergosterol-mevalonate
pathway as a candidate for the cellular response to α-synuclein
toxicity. One of the identified genes is Hrd1, a ubiquitin protein
ligase related with the regulation of HMG-CoA reductase, the
rate-limiting enzyme for the de novo Chol synthesis (Yeger-
Lotem et al., 2009). They also found that pharmacological
inhibition of HMG-CoA reductase by statins makes yeasts more
vulnerable to α-synuclein toxicity (Yeger-Lotem et al., 2009).
Our results in dopaminergic neurons and those obtained in
yeasts suggest a protective role of neutral lipids (TAG and Chol)
during α-synuclein overexpression either against proteotoxicity
or against oxidative stress (Yeger-Lotem et al., 2009; Auluck
et al., 2010; Sánchez Campos et al., 2018). However, contrasting
effects have been reported in primary human neurons treated
with statins (Bar-On et al., 2008; Roy and Pahan, 2011). In
view of the above, additional studies are needed to understand
the biological significance of these controversial experimental
evidences. Concerning this matter, the clinical relevance of statins
is still under debate and is currently being addressed in a trial
with PD patients treated with simvastatin which ends in 2020
(Carroll and Wyse, 2017).
The accumulated data allows us to propose a biological
function for α-synuclein as a lipid metabolism modulator. Both
at physiological levels and when overexpressed, α-synuclein is
able to trigger a metabolic switch involving several aspects
of lipid biology (Figure 2). The main biological response to
α-synuclein overexpression is an increase in neutral lipid content
that could be related to a neuroprotective strategy, whereas
under physiological conditions the modulation of AA levels
by the protein appears to be associated with prostaglandin
generation and thus with a role in the inflammatory cascade
(Golovko et al., 2007).
The open question is how α-synuclein triggers the
above-mentioned metabolic changes. One possibility is that the
switch in neutral lipid metabolism in terms of LD accumulation
could be a consequence of endoplasmic reticulum stress and
autophagy impairment, triggered by proteotoxicity due to
the overexpression of α-synuclein (Velázquez et al., 2016;
Garcia et al., 2018; Pitcairn et al., 2018). The other possibility
is that α-synuclein could be involved in the regulation of
gene expression associated with lipid metabolism. This latter
possibility relates to the high DNA affinity of amyloidogenic
proteins, the nuclear localization of α-synuclein, and its
participation in epigenetic modifications through histone
acetylation (Ma et al., 2014; Surguchev and Surguchov, 2017).
Specifically, it has been described that α-synuclein modulates
gene expression related with cell survival by decreasing H3
acetylation (Pavlou et al., 2017) and with ubiquitination (Martins
et al., 2011). Additional studies will be required to ascertain
which of the above-mentioned mechanisms are biologically and
pathologically involved and their link with lipid metabolism.
α-SYNUCLEIN AND LIPID SIGNALING
Apart from their structural and biophysical role in biological
membranes, lipids also serve as reservoirs of intracellular and
extracellular messengers. One of the most investigated events in
lipid signaling is the action of phospholipases and PL kinases
and phosphatases that produce different lipid and non-lipid
messengers from membrane PLs.
Phospholipases catalyze the hydrolysis of acyl and phosphate
esters and are named according to their hydrolyzed position on
the PL molecule. Among them, PLA2 and phospholipases C and
D (PLC and PLD) are widely studied and many of them have been
implicated in neurodegenerative processes.
Phospholipases A2 catalyzes the hydrolysis of the fatty acid
esterified in the sn-2 of the glycerol backbone of PL moieties
and releases FFA and a lysophospholipid. There are currently
six different known types of PLA2: secreted (groups I, II, III,
V, IX, X, XI, XII, XIII, and XIV), cytosolic (cPLA2, group IV),
calcium-independent (iPLA2, group VI), lipoprotein (groups VII
and VIII), adipose (group XVI) and lysosomal (group XV),
together constituting an enzyme superfamily (Dennis et al., 2011;
Vasquez et al., 2018). In terms of neurodegenerative processes,
and specifically PD, the most studied PLA2 isotypes are cPLA2
and iPLA2. The classical role assigned to iPLA2 enzymes is
their active participation in membrane homeostasis through PL
remodeling in Lands cycle where phospholipase activity operates
coordinately with PL-acyltransferases. Later findings postulate
other important functions for iPLA2s: while lysophosphatidyl
moieties have been shown to modulate store-operated calcium
entry, the released fatty acid, mostly DHA, has been described
as the preferred substrate for the production of resolvins, lipid
mediators involved in the resolution of inflammatory processes
(Bazan, 2005; Serhan and Petasis, 2011). iPLA2 are mainly
encoded by the PLA2G6 gene. In the nervous system, iPLA2β
has been shown to be essential for remodeling membrane
PLs in axons and synapses. Mutations in PLA2G6 have been
associated with several neurodegenerative disorders, including
adult-onset dystonia-parkinsonism, PARK14. In this regard,
PLA2G6 knock-out mice have been widely used for the study
of neuronal membrane-associated degeneration (Sumi-Akamaru
et al., 2016). Indeed, increased expression of α-synuclein has
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been associated with mitochondrial injury triggered by iPLA2
dysfunction in PLA2G6 knock-out animals (Sumi-Akamaru
et al., 2016). Moreover, the impairment of iPLA2-dependent
calcium signaling has recently been implicated in neuronal
loss through autophagic dysfunction in dopaminergic neurons
derived from fibroblasts from PD patients and PLA2G6
knock-out animals (Zhou et al., 2016).
cPLA2 is mainly associated with the release of AA, the
obligate substrate for prostaglandins generation catalyzed by
cyclooxygenase-2, which is considered one of the main pathways
mediating inflammatory response. Though neuroinflammation is
a hallmark of PD, the specific PLA2 isoforms that are activated
in dopaminergic neuronal damage have not been fully described.
Besides the classical inflammatory process, the exposure to
extracellular α-synuclein is able to activate cPLA2 and to promote
synapse damage induced by phospholipase-dependent activity
(Bate and Williams, 2015).
Upon PLA2 activation, it is important that fatty acid release
be properly coupled to PL acylation activity; impairment of
the Lands cycle could be responsible for an increase in FFA
availability (DHA, AA). This increase in FFA availability,
could in turn, be associated with α-synuclein and promote
its oligomerization. The rise in cytosolic/soluble DHA content
reported by Sharon and coworkers in post-mortem brains in PD
and LB dementia patients is in agreement with the activation of
any specific PLA2 that could consecutively induce α-synuclein
oligomerization and aggregation (Sharon et al., 2003a). The
workings of this mechanism still lack clarity.
The fact that SNCA knock-out mice present enhanced
prostaglandin generation during neuronal injury argues in
favor of a biological role for α-synuclein in the regulation
of the inflammatory cascade (Golovko and Murphy, 2008).
It has been demonstrated that DHA, mainly released from
PLs by iPLA2 action, has a long half-life compared with
other fatty acids and that its free form is the preferred
substrate for neuroprotectin synthesis, and the resolution
of the inflammatory process (Murphy, 2013). An important
question is whether the dyshomeostasis between cPLA2 and
iPLA2 triggered by α-synuclein overexpression could be
responsible for a differential AA/DHA ratio and availability, thus
modulating the balance between inflammation and resolution
processes and promoting the neuroinflammatory phenotype
in PD (Figure 3).
Among the classical signaling pathways associated with
G-protein-coupled receptors is PI-specific PLC. Upon receptor
activation, PLC hydrolyzes PI 4,5-bisphosphate to produce
the lipid messenger diacylglycerol and the soluble inositol
triphosphate. There are now six different families of PLC
(β, γ, δ, ε, ζ, and η) described in different tissues, with
pleiotropic functions associated with the membrane receptor
to which they are coupled (Kadamur and Ross, 2013). It
has recently been shown that α-synuclein overexpression
interferes with Gq/PLC-β signaling by preventing the rise
in cytosolic calcium and ERK 1/2 activation (Volta et al.,
2017). α-Synuclein is also able to trigger the impairment of
G-protein signaling associated with sphingosine-1-phosphate
by promoting the exclusion of the receptor from lipid rafts
(Mohamed Badawy et al., 2018).
Phospholipase D signaling impairment has been reported
in Alzheimer’s disease and the signaling pathway is, therefore,
an emerging therapeutic target for this neurodegenerative
disorder (Brown et al., 2017). The role of PLD in α-synuclein-
associated pathologies, however, still lacks clarity. Classical
PLDs, PLD1 and PLD2, catalyze the hydrolysis of the PC
head group in order to produce PA. PA has pleiotropic
functions both as a lipid messenger, regulating the activity of
signaling proteins, and as an important modulator of membrane
curvature. Whereas neuronal PLD1 has been associated with
cytoskeleton architecture, PLD2 activity is linked to molecular
events triggered by the activation of membrane receptors
(Watanabe et al., 2011; Comoglio et al., 2014). Both PLD1
and PLD2 have been reported to participate in astroglial
differentiation (Burkhardt et al., 2015). Genetic deletion of
PLD1 or PLD2 in transgenic mice demonstrates that both
FIGURE 3 | α-Synuclein and the modulation of lipid signaling. α-Synuclein is able to intervene lipid signaling by the modulation of phospholipase activities. The
α-synuclein -induced impairment of cPLA2 and iPLA2 signaling triggers an imbalance in the AA/DHA ratio that finally could affect the balance of inflammation and
resolution processes. Calcium signaling and ERK 1/2 activation are modulated by α-synuclein through PLC pathway impairment. α-Synuclein intervention in PLD
signaling impacts on diverse cellular functions as vesicular trafficking, membrane curvature, and membrane protein targeting, lysosomal activity and PA-dependent
signaling. AA, arachidonic acid; DHA, docosahexaenoic acid; PA, phosphatidic acid; cPLA2, calcium-sensitive cytosolic phospholipase A2; iPLA2,
calcium-independent phospholipase A2; PLC, phospholipase C; PLD, phospholipase D.
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enzymes participate in brain development and cognitive function
(Burkhardt et al., 2014).
The role of classical PLDs in the several processes of
the nervous system has been well-established, but their
participation in neurodegenerative processes associated with
synucleinopathies is not clear. In vitro and in vivo assays
have given rise to a number of divergent reports of the role
of α-synuclein in PLD signaling. In vivo experiments have
demonstrated that α-synuclein-induced PLD2 inhibition is able
to prevent dopaminergic neurodegeneration (Gorbatyuk et al.,
2010), whereas in vitro assays using recombinant α-synuclein
and purified PLD1 and PLD2 have shown no inhibition of PLD
activity (Rappley et al., 2009). However, protein profile studies in
post-mortem brains from PD patients display diminished PLD1
expression (Bae et al., 2014). In yeast, it has been demonstrated
that PLD inhibition elicited by α-synuclein was related to
dysregulation of lipid metabolism and trafficking (Outeiro and
Lindquist, 2003). In line with this, our laboratory has recently
described that the overexpression of human α-synuclein in
neuroblastoma cells is able to induce a decrease in PLD1
mRNA and protein levels and to impair ERK1/2 signaling
(Conde et al., 2018). In this cellular model of synucleinopathy,
we demonstrated that the inhibition of PLD1 expression and
the impairment of ERK1/2 signaling triggered by α-synuclein
overexpression are associated with a decrease in neurofilament
light chain expression and in consequence with alteration of
the neuronal cytoskeleton. The reported findings highlight the
biological significance of PLD regulation exerted by α-synuclein
that could modulate PA levels in a compartment-specific
manner, thus impacting on different cellular functions: (i)
vesicular trafficking, (ii) membrane curvature and membrane
protein targeting, (iii) lysosomal activity, and (iv) PA-dependent
signaling, among others (Figure 3).
It is clear from the above that α-synuclein, mainly when it
is overexpressed, is able to disturb lipid signaling. The plethora
of lipid messengers (PA, AA, DHA, and diacylglycerol) able to
be produced due to α-synuclein could have different impacts
on important cellular processes in the nervous system such
as vesicular trafficking, autophagy, cytoskeleton architecture,
and neuroinflammation. Dissecting the signaling pathways
responsible for the production of each lipid messenger and
the specific cellular compartment where they work, could
contribute to the development of new strategic therapies
for synucleinopathies.
CONCLUDING REMARKS
This review covers the diversity of ways in which α-synuclein
interacts and connects with lipid biology. Much of the
experimental evidences dealing with the physical interaction of
the protein with different lipid moieties derive from biophysical
studies performed on artificial membranes. It is clear that
the α-synuclein N-terminal domain is able to interact with
the majority of PLs and with Chol with different affinities.
Further research is required in order to shed more light
on precisely which of these α-synuclein/lipid interactions
occur in vivo; clear findings will undoubtedly contribute to a
fuller understanding of both the biological and pathological
implications of α-synuclein.
Efforts toward a more detailed characterization of α-synuclein
interventions in lipid metabolism and signaling will open
the way to a more in-depth assessment of the protein’s
implications for therapeutic purposes. One hypothesis to be
tested is whether α-synuclein pleiotropic properties are able
to trigger a lipid metabolic and signaling switch, creating
a propensity to interact and aggregate thus establishing a
positive feedback. Unraveling this paradigm could provide
not only new insights into the biological role of α-synuclein
but also innovative ways of devising strategies for the
treatment of synucleinopathies.
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